Join to View Full Profile
200 HAWKINS DRUROLOGY - 3RCPIowa City, IA 52242
Phone+1 319-353-8771
Fax+1 319-356-3900
Dr. Odonnell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael ODonnell is a urologist based in Iowa City, IA, specializing in urologic oncology, bladder cancer, and male sexual dysfunction. He completed his medical education at Duke University School of Medicine, followed by residencies in surgery and urology at Brigham and Women's Hospital/Beth Israel/Harvard Medical School. Dr. ODonnell has published over 200 manuscripts on bladder cancer treatments in many high-profile journals and he is the inventor of the intravesical gemcitabine/docetaxel (gem/doce) treatment. His work has been frequently cited in other publications putting him in the top 2% in the nation. He has received several national awards including the Von Eschenbach and BCAN Innovation award.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Harvard Medical SchoolResidency, Urology, 1987 - 1991- Mass General Brigham/Brigham and Women's HospitalResidency, Surgery, 1985 - 1987
Duke University School of MedicineClass of 1984
Certifications & Licensure
IA State Medical License 2000 - 2026
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Outgoing Public Health Reporting from EpicCare Functionality, Epic Systems Corporation, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2014, 2016-2017
Publications & Presentations
PubMed
- 41 citationsA Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasi...Noah M Hahn, Michael A O'Donnell, Jason A Efstathiou, Marianna Zahurak, Gary L Rosner
European Urology. 2023-06-01 - 43 citationsLong-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer.Phani T Chevuru, Ian M McElree, Sarah L Mott, Ryan L Steinberg, Michael A O'Donnell
Urologic Oncology. 2023-03-01 - 1 citationsRe: Khyati Meghani, Lauren Folgosa Cooley, Bonnie Choy, et al. First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unr...Ryan L Steinberg, Michael A O'Donnell, Vignesh T Packiam
European Urology. 2023-02-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
